Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer

Autor: Gandhi, Leena, Rodríguez-Abreu, Delvys, Gadgeel, Shirish, Esteban, Emilio, Felip, Enriqueta, De Angelis, Flávia, Domine, Manuel, Clingan, Philip, Hochmair, Maximilian J, Powell, Steven F, Cheng, Susanna Y-S, Bischoff, Helge G, Peled, Nir, Grossi, Francesco, Jennens, Ross R, Reck, Martin, Hui, Rina, Garon, Edward B, Boyer, Michael, Rubio-Viqueira, Belén, Novello, Silvia, Kurata, Takayasu, Gray, Jhanelle E, Vida, John, Wei, Ziwen, Yang, Jing, Raftopoulos, Harry, Pietanza, M Catherine, Garassino, Marina C, KEYNOTE-189 Investigators, Ocak, Sebahat

Publikováno v: The New England Journal of Medicine, 378, 22, pp. 2078-2092
The New England journal of medicine, Vol. 378, no. 22, p. 2078-2092 (2018)
The New England Journal of Medicine, 378, 2078-2092

Contains fulltext : 193627.pdf (Publisher’s version ) (Open Access) BACKGROUND: First-line therapy for advanced non-small-cell lung cancer (NSCLC) that lacks targetable mutations is platinum-based chemotherapy. Among patients with a tumor proportio

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fd80b53e7baf247aa76594edc561e889
https://hdl.handle.net/2066/193627